Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stricter Checks on Medicines

This article was originally published in PharmAsia News

Executive Summary

Xinhua News Agency (01/28/07) Starting in the second half of 2007, Chinese authorities plan to review close to 170,000 drug approvals in order to retest drugs, examine their market track record in official databases, and remove inadequate drugs from the Chinese marketplace. The review will apply to drugs that won Good Manufacturing Practice (GMP) certificates in 2004 and 2005. The Chinese pharmaceutical industry contains numerous companies that copy existing products and sell them under a new name for higher than usual prices. China Galaxy Securities analyst Liu Yanming says revoking licenses will improve market competitiveness, spur more research and development, and likely lead to mergers in China's drug industry. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts